Evaluating Lu-177-radiolabelled antibodies for TNBC theranostics
23/09/2024
SPECT images captured by the γ-CUBE showing 177Lu accumulation in tumors in a subcutaneous TROP-2 positive TNBC xenograft mice model.
At a glance
> In a recent study, the MOLECUBES γ-CUBE has been used to image antibodies radiolabelled with 177Lu to evaluate its effectiveness in treating triple-negative breast cancer (TNBC).
> TNBC is one of the most aggressive types of cancer in women, characterized by a lack of specific receptors which can be targeted with traditional hormone therapy.
> The benchtop γ-CUBE showed clear and specific accumulation of the radiolabelled antibodies in TROP-2-positive tumors.
Evaluating theranostics for triple-negative breast cancer
In a recent study by Wu et al., the MOLECUBES γ-CUBE for preclinical SPECT imaging was used to image antibodies radiolabelled with 177Lu to evaluate the effectiveness for theranostics in treating triple-negative breast cancer (TNBC). TNBC is one of the most aggressive types of cancer in women, characterized by a lack of specific receptors, such as estrogen, progesterone, and HER2, which can be targeted with traditional hormone therapy.
The protein Trophoblast cell-surface antigen-2 (TROP-2) is commonly overexpressed in TNBC patients. The radiolabelled antibody developed by Wu et al. allows TROP-2 levels in tumors to be non-invasively quantified to determine future possible treatments.
High-resolution SPECT imaging
The MOLECUBES γ-CUBE showed clear and specific accumulation of the radiolabelled antibodies in TROP-2-positive tumors, showing markedly higher signal than the control groups. Ex vivo biodistribution and histological analysis validated the SPECT imaging results, further supporting the precise localisation of the 177Lu-labelled antibodies. Consequently, high-resolution SPECT imaging allowed Wu et al. to accurately monitor responses and validate the theranostic potential of the 177Lu-radiolabelled antibodies to treat TNBC.
Find out more
You can learn more about MOLECUBES γ-CUBE by clicking the button below to speak to a product specialist directly.